Ertapenem sodium side effects
33 Employee costs continued The UK defined benefit schemes also have defined contribution sections with account balances totalling 281 million at 31st December 2002 2001 263 million ; . The defined benefit sections of the UK schemes have been closed to new members, and under the projected unit method of valuing the pension scheme liabilities the current service cost will increase as the members of the schemes approach retirement. The deficits under FRS 17 reflect the different bases for valuing assets and liabilities compared with SSAP 24, including the immediate impact of the fair values of assets at 31st December 2002. The Group also operates a number of unfunded post-retirement healthcare schemes, the principal one of which is in the USA. The liability under FRS 17 for the US scheme has been assessed using the same assumptions as for the US pension scheme, together with the assumption for future medical inflation of 11 per cent, reducing by one per cent per year to five per cent. On this basis the liability for the US scheme has been assessed at 766 million 2001 787 million ; , which reduced to 475 million 2001 488 million ; after taking account of deferred tax. If the defined benefit pension and post-retirement benefit schemes had been accounted for under FRS 17, the following amounts would have been recorded in the profit and loss account and statement of total recognised gains and losses for the year ended 31st December 2002.
In organisms at 24 h between 1 and 3 log10 for the majority of the isolates tested. For each ESBL isolate examined, encompassing a wide MIC range, meropenem displayed either decreased or static activity. Bacteriostasis 0.04-log kill ; was observed even for K. pneumoniae 262 MIC 8 g ml ; , which is considered intermediate according to CLSI-defined breakpoints. On the other hand, ertapenem resulted in bacterial kill up to an MIC of 1.5 g ml, above which bacteria grew between approximately 0.5 to 3.5 logs. Ertapenem, however, did show efficacy against K. pneumoniae 264, with an MIC of 4 g ml, which is defined as intermediate by CLSI susceptibility breakpoints. No difference in bacterial kill was observed for either carbapenem for the majority of the ESBL isolates tested, because the MICs were low 0.5 g ml for meropenem; 1.5 g ml for ertapenem ; . This corresponded to fT MICs of 75% and 23% for meropenem and ertapenem, respectively. For seven of the eight ESBL isolates with ertapenem MICs of 2 g ml, greater bacterial kill was observed in the mice given meropenem. This is most likely due to the two- to eightfold-greater in vitro potency of meropenem, which resulted in an fT MIC of 30 to 65%, compared with the ertapenem fT MIC of 20%. For the two non-ESBL isolates tested, ATCC 25922 and E. coli 120, an approximate 2-log decrease in CFU thigh was observed for both meropenem and ertapenem. Because of the low MICs of these organisms, the fT MIC was high 77 to 93% ; . These isolates showed kills similar to those of ESBL isolates with similar MICs. For the three isolates E. coli 315, E. coli 321, and E. coli 322 ; that were tested at a 100-fold-higher inoculum 107 ; , the bacterial density for the 0-h control group was 7.40 0.08 log10 CFU thigh. Unlike at the standard 105 inoculum, the 24-h control group did not grow well, with a mean difference of 0.08 0.33 log10 CFU thigh. Despite the higher MICs at this inoculum, which led to corresponding fT MICs of 30 to 45% and 20 to 30% for meropenem and ertapenem, respectively, approximately 2- to 3.5-log decreases in bacteria were observed.
Action of ertapenem sodium
Unstimulated and stimulated whole saliva samples were collected over a 2-minute period using saliva sampling tubes Salivette; Sarstedt, Leics, England ; according to a previously reported modified swab method.5-7 Briefly, each subject was asked to swallow in order to empty his mouth; he then placed the polyester swab in the floor of his mouth and rolled it around the oral cavity for exactly 2 minutes, absorbing saliva from all major and minor salivary glands. Stimulated whole saliva samples were also collected from each subject after 2% citric acid was applied to the dorsal surface of the anterior tongue at 30second intervals. The saliva volume was estimated by centrifuging the saliva sampling tube at 1000g for 5 minutes. The SFR was determined by dividing the volume of saliva by the collection time. All subjects refrained from eating, drinking, and smoking for a minimum of 90 minutes before saliva collection and were seen in the morning. No subject had a history of taking medication to reduce salivation. Self-perceived scores for dry mouth were obtained from the participants. The scores rated symptoms on a 100-mm visual analog scale, with higher scores indicating greater dryness or stickiness. The salivary flow and xerostomia scores were measured in each subject before and every 30
Figure 7. Rare NK clones derived from healthy donors are unable to kill TAP2 PHA blasts. left panel ; Representative experiment in which a large number of NK clones derived from a healthy donor C.B. ; were assessed for cytolytic activity against E.M.O. PHA blasts in the presence of anti-HLA class I mAb each square represents the cytotoxicity of an individual clone ; . right panel ; NK clones displaying no cytolytic activity against E.M.O. PHA blasts were also unable to kill autologous or heterologous PHA blasts but killed B-EBV target cells. In this experiment, a representative clone CB 520 ; was assessed for cytotoxicity against the indicated target in the absence white bars ; or in the presence black bars ; of anti-HLA class I mAb. The E: T ratio was 10: 1 PHA blasts ; or 4: 1 B-EBV targets.
Results In 2000, the first year after GnRH antagonists became available, 37 230 GnRH agonist long protocol and 7821 GnRH antagonist ovarian stimulation cycles were initiated. By 2003, GnRH antagonist utilization had increased 2.89-fold to a total number of 22 614 initiated ovarian stimulation cycles. In contrast, 53 151 GnRH agonist cycles were recorded in 2003, which translates into a 1.42-fold increase of GnRH agonist long protocol utilization from 2000 to 2003 Figure 1 ; . Whereas in the year 2000 about one in seven ovarian stimulation cycles was conducted using GnRH antagonists, in 2003 about one in four cycles was conducted using GnRH antagonists P , 0.0001 ; . Stratified by cycle rank, the proportion of GnRH antagonist cycles increases from 23.3%in first treatment cycles, to 35.5% in fifth treatment cycles, and to 47.8% in tenth treatment cycles P , 0.0001; Figure 2 ; . The same trend was observed for stimulation protocols other than GnRH agonist long or GnRH antagonist e.g. GnRH agonist short, or stimulation regimen without GnRH analogue; data not shown ; . From a total of 272 862 cycles, 117 854 40.2% ; were conducted in a first treatment cycle. With higher cycle ranks, the.
Ertapenem for enterococcus
149; if you are using ertapenem at home, your healthcare provider will give you detailed instructions regarding preparation, administration, and storage of the medication and esmolol.
Date 5 Oct 7 Oct 8 Oct 12 Oct Time 2: 00pm to 6: 00pm 12: 45pm to 1: 45pm 12.45pm to 2.00pm 2: 00pm to 6: 00pm 12: 45pm to 1: 45pm 12.45pm to 2.00pm 1: 15pm to 2: 00pm 1: 15pm to 2: 00pm 1: 15pm to 2: 00pm 1: 15pm to 2: 00pm 1: 00pm to 5: 00pm 12: 45pm to 1: 45pm 12.45pm to 2.00pm 1: 15pm to 2: 00pm 1: 15pm to 2: 00pm 1: 45pm to 5: 45pm 8: to 5: 30pm 8: to 12: 55pm 1: 00pm to 5: 00pm 2: 00pm to 6: 00pm 12: 45pm to 1: 45pm 12.45pm to 2.00pm 1: 15pm to 2: 00pm 12: 30pm to 2: 00pm Venue Lecture Rm, Level 2, NSC Lecture Hall, Level 2, IMH Diabetes Centre, Function Rm, AH Lecture Rm, Level 2, NSC Lecture Hall, Level 2, IMH Diabetes Centre, Function Rm, AH Hougang Polyclinic Course Topic
Ear Wax, Removal of . 217 Easi-Breathe . 39, 42 Econazole . 161 Eczema, Preparations for . 226 Eczema Dermatitis, Management of . 239 Edrophonium . 202 Efavirenz. 104 Efexor XL. 56 Elleste preparations . 144, 146, 157 Elocon . 225 Emergency Contraception . 163 Emla . 250 Emollients . 221, 234, 235 Emulsiderm . 222, 234, 239 Enalapril. 18 Enlive Plus . 187 Enoxaparin. 22, 23 Enrich Plus . 186 Ensure Plus . 186, 187 Entacapone. 70, 89, 90, Enuresis. 164, 165 Epaderm .221, 222, 234, Epanutin Infatabs . 67 Ephedrine . 21 Epilim Chrono . 66 EpiPen . 45 Epirubicin . 172 Epistaxis . 219 Eplerenone . 14 Epoetin Beta . 181 Epoprostenol. 22 Equasym XL . 57 Erectile Dysfunction, Drugs used for. 167 Ergometrine . 160 Ergotamine . 65 Erlotinib. 173 Ertapenem . 102 Erythromycin 41, 97, 108, Esmolol . 16 Estraderm MX . 146, 157 Estradiol. 158, 161 Estradot . 146, 157 Estramustine. 171 Estriol. 158, 161 Etanercept . 201 Ethambutol. 102 Etomidate. 248 Etoposide. 173 Eumovate . 224, 240 Eurax . 223 Evorel preparations. 145, 146, 157 Evra. 162 Exemestane. 175, 178 Exenatide. 140 Exorex . 226, 240 Ezetimibe . 25 and estramustine.
Objectives: To describe the current patterns of antimicrobial resistance in the major pathogens of bacteraemia in the UK and Ireland, to highlight any unexpected resistance patterns and to act as a reference baseline for future studies. Methods: In 2001 and 2002, 5092 blood culture isolates were collected by 29 laboratories distributed across the UK and Ireland. A single central laboratory re-identified the isolates and measured MICs by the BSAC agar dilution method. Results: Oxacillin resistance was found in 42% of Staphylococcus aureus and 76% of coagulase-negative staphylococci. Streptococci were generally susceptible to -lactams, but tetracycline resistance was common except in Streptococcus pneumoniae ; and particularly common among group B isolates 82% resistant ; . Nine percent of S. pneumoniae had reduced susceptibility to penicillin MICs 0.121 mg L ; , but none required 2 mg L for inhibition. High-level gentamicin resistance was seen in 43% of Enterococcus faecalis, often in combination with raised ciprofloxacin MICs 32 mg L ; , but these isolates remained susceptible to ampicillin and imipenem. Only linezolid and tigecycline showed in vitro potency against a large proportion of Enterococcus faecium. Vancomycin resistance was restricted to enterococci 20% of E. faecium, 3% of E. faecalis ; and a single isolate of coagulase-negative staphylococci 0.2%, MIC of 8 mg L ; . Escherichia coli isolates were commonly resistant to amoxicillin 56% ; and tetracycline 88% ; but remained susceptible to ceftazidime, piperacillin tazobactam and imipenem. Extended-spectrum -lactamases were detected in 2% of E. coli none in 2001, 3.2% in 2002 ; , 5% of Klebsiella spp. and 8% of Enterobacter spp. Resistance rates of Pseudomonas aeruginosa to ciprofloxacin, ceftazidime, gentamicin, imipenem and piperacillin tazobactam were between 4% and 7%. Among the newly licensed and developmental agents, there was no resistance to linezolid in Gram-positive organisms. Ertapenem had a wide spectrum, covering Enterobacteriaceae, streptococci and oxacillin-susceptible staphylococci. MICs of tigecycline were low for Gram-positive species and Enterobacteriaceae except Proteeae and Enterobacter spp. Conclusion: Antimicrobial resistance among major bloodstream pathogens to those antimicrobials often selected for empirical therapy was relatively uncommon in 20012002, usually 10%. An important exception was oxacillin resistance in S. aureus.
Ertapenem prescription
The pharmacokinetics of ertapenem either alone or against comparators are displayed in TABLES 4 & 5. Single-dose ertapenem studies ranging from 0.4 to 3 g were conducted in healthy young subjects TABLE 4 ; [27]. The results illustrated somewhat less than dose proportional increases in plasma concentrations and area under the plasma concentrationtime curve AUC ; with increasing dose, due to the nonlinear concentration-dependent protein binding of ertapenem [27, 28]. After repeated daily infusions, ertapenem did not show any evidence of accumulation in young or elderly healthy individuals [27, 29]. Slight gender differences in pharmacokinetic parameters in both healthy young and elderly women were attributed to the lower body weight of females and are not considered to be clinically relevant; consequently there are no recommendations for dose adjustments based on gender [27]. In the elderly, higher plasma concentrations, an overall decrease in plasma clearance of ertapenem, and a slightly increased half-life were associated with an increase in mean AUC 39% of total ertapenem and 71% of unbound drug ; compared with young healthy subjects [29]. Elderly subjects also tend to have a slightly higher percentage of unbound and eszopiclone.
All correspondence should be sent to Ronald T. Brown, College of Health Professions, Medical University of South Carolina, 19 Hagood Avenue, Suite 910, P Box 250822, Charleston, South Carolina 29452. E-mail: .O. brownron musc.
Tax increases in 2003. If most states address their deficit issues this year, we could see less activity in 2004. In December 2002, we recorded a 4 million pre-tax restructuring charge, yielding annualized cost savings. In addition, Reynolds Tobacco's MSA costs will also decline somewhat in 2003. However, higher investments in brand equity, higher promotional spending and lower volumes -- combined with greater pension expense resulting from unfavorable financial market conditions -- will more than offset the cost savings. Having streamlined our cost structure and positioned key brands for growth, it is our goal to position the company to deliver higher earnings and improved marketplace performance long-term and ethionamide.
9: 30 - 11: 30 12: 00 - 12: 55 1: 00 Dermatology Procedures & Coding Daniel J. Van Durme, MD, Tallahassee Syllabus Review Friday Afternoon Topics ; New Drug Update Robert Vandervoort, PharmD, Orlando 10 Things I Wish I Knew Last Year Louis Kuritzky, MD, Gainesville Refreshment Break & Exhibit Visitation Sickle Cell Disease in Kids and Adults Jose Rodriguez, MD, Tallahassee Academy Update by FAFP President Neil Oslos, MD Bio-identical HRT Eldridge Taylor, MD, Atlanta, GA
MATERIALS AND METHODS Strains. The penicillin-resistant pneumococcal strain WB4 serotype 6 was isolated from a patient with pneumonia at the University Hospital of Bern, Bern, Switzerland. The MICs for this strain were as follows: penicillin, 4 mg liter; ceftriaxone, 0.5 mg liter; vancomycin, 0.12 to 0.25 mg liter; and ertapenem 0.5 mg liter. The penicillin-sensitive strain was kindly provided by the Institute for Infectious Diseases, University of Bern MICs for this strain: penicillin, 0.05 mg liter; ceftriaxone, 0.05 mg liter; and ertapenem, 0.03 mg liter ; . The penicillinand quinolone-resistant mutant was obtained by sequential exposure of the penicillin-resistant strain to trovafloxacin in vitro. The MICs for this strain were as follows: penicillin, 4 mg liter; ertapenem, 0.5 mg liter; trovafloxacin, 4 mg liter; and ciprofloxacin, 32 mg liter. Rabbit meningitis model. The meningitis model, originally described by Dacey and Sande 8 ; was slightly modified. The experimental protocol was accepted by the Veterinaramt des Kantons Bern. In brief, young New Zealand White rabbits weighing 2 to 2.5 kg were anesthetized by intramuscular injections of ketamine 30 mg kg ; and xylazine 15 mg kg ; and were immobilized in stereotactic frames for induction of meningitis and CSF sampling. An inoculum containing approximately 1 105 to 106 CFU of penicillin-sensitive or penicillin-resistant pneumococci serotype 6, was directly injected into the cisterna magna. A long-acting anesthetic ethyl carbamate [urethane], 3.5 g rabbit ; was injected subcutaneously, and animals were returned to their cages. Fourteen hours later, the cisterna magna was punctured again for periodic CSF sampling before and 1, 2, 4, and 8 h after the initiation of therapy. A catheter was introduced into the femoral artery for serum sampling. Antibiotics were administered through a peripheral ear vein as bolus injections at the following doses: ceftriaxone, 125 mg kg; vancomycin, 20 mg kg; and ertapenem, 60 mg kg. These dosages achieve serum concentrations similar to those observed in humans. Ceftriaxone was injected once at 0 h and vancomycin at 0 and 4 h according to Friedland et al. 9 ; and Cottagnoud et al. 6 ; . Ertapenem was injected once at 0 h. Untreated controls received saline. Ertapenem was kindly provided by MSD. The other antibiotics and anesthetic drugs were commercially purchased. Bacterial titers were measured by 10-fold serial dilutions of CSF samples plated on blood agar plates containing 5% sheep blood and incubated overnight at 37C. In parallel, 20 l of undiluted CSF samples was plated limit of detectability, 50 CFU ml ; . Comparisons between different dilutions of CSF were used to exclude significant carryover effects during therapy. The antimicrobial activity of the regimens during the 8-h treatment was calculated by linear regression analysis and expressed as a decrease in log10 CFU per milliliter per hour and as a killing rate over 8 h. A value of 1.7 log10 CFU ml the limit of detectability ; was assigned to the first sterile CSF sample, and a value of 0 log10 CFU ml was assigned to any following sterile sample. The results were expressed as means standard deviations. The statistical significance was determined by the NewmanKeuls test. In the same experimental setting, ertapenem 60 mg kg ; was injected into uninfected animals in order to measure the penetration of ertapenem through uninflamed meninges. Sampling was performed as described above. Ten rabbits were used in each ertapenem monotherapy group, and 4 rabbits were in each group for the standard regimens and control groups and ethosuximide.
Ertapenem price
The activities of ertapenem MK-0826 ; and eight other agents against a range of penicillin-susceptible and -resistant pneumococci were tested by determination of MICs by the microdilution method and by the time-kill methodology. For 125 penicillin-susceptible, 74 penicillin-intermediate, and 86 penicillin-resistant pneumococci, the MICs at which 50% of isolates are inhibited MIC50s ; and MIC90s, as determined by the microdilution method, were as follows: for ertapenem, 0.016 and 0.03, 0.125 and 0.5, and 0.5 and 1.0 g ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for amoxicillin, 0.016 and 0.03, 0.25 and 1.0, and 2.0 and 2.0 g ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for cefprozil, 0.125 and 0.25, 1.0 and 8.0, and 16.0 and 16.0 g ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for cefepime, 0.016 and 0.06, 0.5 and 1.0, and 1.0 and 2.0 g ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for ceftriaxone, 0.016 and 0.06, 0.25 and 1.0, and 1.0 and 2.0 g ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; for imipenem, 0.008 and 0.008, 0.03 and 0.25, and 0.25 and 0.25 g ml for penicillin-susceptible, penicillinintermediate, and penicillin-resistant pneumococci, respectively; for meropenem, 0.008 and 0.016, 0.125 and 0.5, and 0.5 and 1.0 g ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively; and for clarithromycin, 1.0 and 32.0, 1.0 and 32.0, and 32.0 and 32.0 g ml for penicillin-susceptible, penicillin-intermediate, and penicillin-resistant pneumococci, respectively. For 64 strains for which quinolone MICs were increased ciprofloxacin MICs, 4.0 g ml ; , the MIC90 of ertapenem was 1.0 g ml and the MIC90s of the other -lactams tested and clarithromycin were 32.0 g ml. Against four penicillin-susceptible, four penicillin-intermediate, and four penicillin-resistant strains, testing by the time-kill methodology showed that ertapenem at two times the MIC was bacteriostatic 99% killing ; after 12 h and bactericidal 99.9% killing ; against all strains by 24 h, with 90% killing of all strains at two times the MIC after 6 h. At the MIC, ertapenem was bacteriostatic against all strains tested after 24 h. Although the bactericidal activity of imipenem at the MIC after 24 h was significantly greater than that of ertapenem, the kinetics of the two drugs at two times the MIC were similar after 24 h. The killing kinetics of clarithromycin were slower than those of ertapenem and other agents, with clarithromycin at two times the MIC having bactericidal activity against seven of eight macrolide-susceptible strains after 24 h. The prevalence of pneumococci resistant to penicillin G and other -lactam and non lactam compounds has increased worldwide at an alarming rate, including in the United States 1, 5, 6, ; . Major foci of resistance presently include South Africa, Spain, Central and Eastern Europe, and parts of Asia 1, 10, 11 ; . A recent survey in the United States showed that 50.4% of 1, 476 clinically significant pneumococcal isolates were not susceptible to penicillin 12 ; . Macrolide resistance was detected in 33% of isolates, including 5% of penicillinsusceptible strains, 37% of penicillin-intermediate strains, and 66% of penicillin-resistant strains. However, no quinoloneresistant strains were isolated 12 ; . The problem of drug-resistant pneumococci is compounded by the ability of resistant clones to spread from country to country and from continent to continent 13, 14 ; . There is a need for agents that can be used to treat infections caused by penicillin-intermediate and -resistant pneumococci 2, 5, 6 ; . Therapeutic modalities include -lactams, macrolides, and quinolones. Because of the mechanism of -lactam resistance in pneumococci, the MICs of all -lactams rise with those of penicillin G, and the clinical utility of an agent is dependent on its pharmacokinetics 1012 ; . The MICs of the available carbapenems are low relative to the MICs of penicillin, with imipenem having the lowest MICs, followed by meropenem 10, 11 ; . Macrolide resistance has already been alluded to 12 ; . Older quinolones such as ciprofloxacin and ofloxacin have moderate in vitro activities against pneumococci, with MICs clustering around the breakpoints, while newer quinolones such as levofloxacin, sparfloxacin, grepafloxacin, gatifloxacin, moxifloxacin, gemifloxacin, clinafloxacin, and sitafloxacin have lower MICs for pneumococci 4, 17, 20, ; . Ertapenem MK-0826; L-749, 345 ; is a new long-acting parenteral carbapenem 7, 8, 16, M. L. van Ogtrop, D. Andes, and W. A. Craig, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 999, 1999; M. L. Van Ogtrop, D. Andes, and W. A. Craig, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-48, 1998 ; . The present study investigates the antipneumococcal activity of ertapenem by i ; determination by the microdilution method of the MICs of.
Ertapenem for osteomyelitis
Table 3. P values for indicated comparisons of DCs on day 7 and etidronate.
Based on information submitted as a result of a complaint and review of the medical record at the receiving hospital for patient # 1, it was determined that patient # 1 did not receive a medical screening examination as required by regulation. The findings include: A delivery note in the medical record for patient #1, showed that the pregnant female patient presented to Broward General Medical Center BGMC ; on April 8, 1997, in labor. The record states that since patient was not "registered" L and D labor and delivery ; refused to examine the patient. The medical record noted that the husband told the personnel at L and D she was going to have the baby if she was having contractions. Through information submitted in a complaint against BGMC, it was learned that the patient then arrived by private automobile at another hospital on April 8. 1997, at approximately 3: 09 p.m. in active labor with contractions two to three minutes apart, fully dilated and had bulging membranes. She delivered a baby at 3: 43 p.m., 34 minutes after arrival. The patient and husband both informed the hospital that they originally went to BGMC to the labor and delivery department and were told they were at the wrong hospital and were directed to another hospital. The patient and husband said the BGMC personnel knew she was having painful contractions and that no examination or screening was offered and ertapenem.
The study group has also discussed whether cytoreductive therapy should be considered in patients 60 years with platelets 600 x 109 l in order to prevent myelofibrosis. It was decided that no such recommendation could be given at the present time and etodolac.
Ertapenem treatment
Moyamoya angiogram, imiquimod hong kong, free full version zuma deluxe, meningococcal vaccine tetravalent conjugate and neurotoxic heavy metals. Dipivefrin hci price, mini protean tetra, fastin look like and how to recuperate outlook express or orudis suppository.
Ertapenem acinetobacter
4rtapenem, ergapenem, ertapen3m, erapenem, ertpaenem, ertapen4m, etrapenem, ertapeem, eratpenem, ertappenem, ertzpenem, ertapeenm, ertapehem, ertapendm, ertapejem, ertapenme, ertapneem, eryapenem, ertapenemm, ertaenem.
Ertapenem prescribing information
Action of ertapenem sodium, ertapenem for enterococcus, ertapenem prescription, ertapenem price and ertapenem for osteomyelitis. Ertapenem treatment, ertapenem acinetobacter, ertapenem prescribing information and what is ertapenem sodium or ertapenem on line.
|
